Skip to main content

Table I Demographic and baseline characteristics (AT population)

From: Efficacy and Safety of Hizentra®, a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

Characteristic Children Adolescents Adults
2–11 years 12–15 years 16–64 years
N = 18 N = 5 N = 28
Gender, n (%)
 Female 5 (27.8) 0 (0) 11 (39.3)
 Male 13 (72.2) 5 (100) 17 (60.7)
Age (years)
 Mean (SD) 7.2 (2.5) 14.0 (1.0) 34.1 (12.7)
 Median (Range) 7.5 (3–11) 14.0 (13–15) 32.5 (16–60)
Weight (kg)
 Mean (SD) 25.9 (11.06) 57.1 (15.84) 69.2 (13.34)
 Median (Range) 22.0 (13–56) 53.3 (36–77) 70.2 (41–96)
BMI (kg/m2)
 Mean (SD) 16.4 (2.88) 20.6 (2.29) 23.3 (3.96)
 Median (Range) 15.3 (12–24) 20.1 (18–23) 23.0 (16–32)
Primary disease
 CVID, n (%) 7 (38.9) 0 (0) 23 (82.1)
 XLA, n (%) 10 (55.6) 5 (100) 5 (17.9)
 ARAG, n (%) 1 (5.6) 0 (0) 0 (0)
  1. AT all treated (23 pediatric patients), N number of patients in age group, SD standard deviation, CVID common variable immunodeficiency, XLA X-linked agammaglobulinemia, ARAG autosomal recessive agammaglobulinemia